Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Drug Discov Devel. 2009 Jul;12(4):458-67.

PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.

Author information

  • 1Pfizer Inc, Neuroscience Medicinal Chemistry, Groton, CT 06340, USA. thomas.a.chappie@pfizer.com

Abstract

PDE10A is a dual substrate PDE that is highly expressed in medium spiny neurons of the striatal complex. The inhibition of PDE10A produces effects that modulate basal ganglia function in ways that suggest a particular therapeutic utility in the treatment of psychosis in schizophrenia. Significant understanding of PDE10A at the molecular level has helped to guide efforts in inhibitor design, and many different inhibitor classes have now been discovered. At least one PDE10A inhibitor has been advanced into clinical trials to begin to test the hypothesis that such agents may be useful in the treatment of psychosis.

PMID:
19562642
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk